Title | A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Mao Y, Balkin DM, Zoncu R, Erdmann KS, Tomasini L, Hu F, Jin MM, Hodsdon ME, De Camilli P |
Journal | EMBO J |
Volume | 28 |
Issue | 13 |
Pagination | 1831-42 |
Date Published | 2009 Jul 08 |
ISSN | 1460-2075 |
Keywords | Amino Acid Sequence, Animals, Binding Sites, Clathrin, Coated Vesicles, Endocytosis, HeLa Cells, Humans, Models, Molecular, Molecular Sequence Data, Mutation, Nuclear Magnetic Resonance, Biomolecular, Phosphatidylinositols, Phospholipids, Phosphoric Monoester Hydrolases, Protein Conformation, Protein Structure, Tertiary, Rats, Sequence Alignment |
Abstract | OCRL, whose mutations are responsible for Lowe syndrome and Dent disease, and INPP5B are two similar proteins comprising a central inositol 5-phosphatase domain followed by an ASH and a RhoGAP-like domain. Their divergent NH2-terminal portions remain uncharacterized. We show that the NH2-terminal region of OCRL, but not of INPP5B, binds clathrin heavy chain. OCRL, which in contrast to INPP5B visits late stage endocytic clathrin-coated pits, was earlier shown to contain another binding site for clathrin in its COOH-terminal region. NMR structure determination further reveals that despite their primary sequence dissimilarity, the NH2-terminal portions of both OCRL and INPP5B contain a PH domain. The novel clathrin-binding site in OCRL maps to an unusual clathrin-box motif located in a loop of the PH domain, whose mutations reduce recruitment efficiency of OCRL to coated pits. These findings suggest an evolutionary pressure for a specialized function of OCRL in bridging phosphoinositide metabolism to clathrin-dependent membrane trafficking. |
DOI | 10.1038/emboj.2009.155 |
Alternate Journal | EMBO J |
PubMed ID | 19536138 |
PubMed Central ID | PMC2711190 |
Grant List | 5T32GM07205 / GM / NIGMS NIH HHS / United States P01 CA046128 / CA / NCI NIH HHS / United States / HHMI / Howard Hughes Medical Institute / United States P30 DA018343 / DA / NIDA NIH HHS / United States CA46128 / CA / NCI NIH HHS / United States DA018343 / DA / NIDA NIH HHS / United States CA 108992 / CA / NCI NIH HHS / United States NS36251 / NS / NINDS NIH HHS / United States R37 NS036251 / NS / NINDS NIH HHS / United States 1 S10 RR19895 / RR / NCRR NIH HHS / United States S10 RR019895 / RR / NCRR NIH HHS / United States DK45735 / DK / NIDDK NIH HHS / United States R01 CA108992 / CA / NCI NIH HHS / United States P30 DK045735 / DK / NIDDK NIH HHS / United States R01 NS036251 / NS / NINDS NIH HHS / United States T32 GM007205 / GM / NIGMS NIH HHS / United States |
Related Institute:
Molecular Imaging Innovations Institute (MI3)